Fujifilm Corporation to Invest $40 Million into New Viral Vector and Advanced Therapy Facility
The new facility, to be located in Boston, MA, will contain experimental and analytical equipment for viral vector and advanced therapy process development and will expand the CDMO’s manufacturing capacity.
Fujifilm Corporation announced on Jan. 5, 2021 that it will invest $40 million into its contract development and manufacturing organization (CDMO), Fujifilm Diosynth Biotechnologies, to establish a new process development and manufacturing facility for viral vectors and advanced therapies in Boston, MA.
Set to begin operations in the fall of 2021, the new facility will contain experimental and analytical equipment for viral vector and advanced therapy process development in order to expand the CDMO’s manufacturing capacity, the company said in a press release. Contract manufacturing services for clinical trials are scheduled to begin at the site in the fall of 2023.
“The strength of Fujifilm’s Bio CDMO business lies in its wide-range of capabilities: process development for a variety of biopharmaceuticals, such as antibodies, recombinant protein, gene therapy, vaccines, oncolytic virus, and more, along with flexible facilities that can adapt to small- or large-scale manufacturing of drug substances, formulation, and packaging,” said Takatoshi Ishikawa, senior executive vice-president and chief life science officer of Fujifilm Corporation, in the press release. “We will continue to leverage our expertise in Bio CDMO to further accelerate our offerings in viral vectors and advanced therapies, with the ultimate goal of fulfilling unmet medical needs.”
“We are strategically establishing this facility in the greater-Boston area where there is a high concentration of biopharmaceutical companies and academia innovating in the field of advanced therapies,” added Martin Meeson, CEO, Fujifilm Diosynth Biotechnologies, in the press release.
Source: Fujifilm Corporation
